{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:50:49Z","timestamp":1781740249616,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Medulloblastoma is the most common paediatric malignant brain cancer and there is a need for new targeted therapeutic approaches to more effectively treat these malignant tumours, which can be divided into four molecular subtypes. Here, we focus on targeting sonic hedgehog (SHH) subtype medulloblastoma, which accounts for approximately 25% of all cases. The SHH subtype relies upon cholesterol signalling for tumour growth and maintenance of tumour-initiating cancer stem cells (CSCs). To target cholesterol signalling, we employed biomimetic high-density lipoprotein nanoparticles (HDL NPs) which bind to the HDL receptor, scavenger receptor type B-1 (SCARB1), depriving cells of natural HDL and their cholesterol cargo. We demonstrate uptake of HDL NPs in SCARB1 expressing medulloblastoma cells and depletion of cholesterol levels in cancer cells. HDL NPs potently blocked proliferation of medulloblastoma cells, as well as hedgehog-driven Ewing sarcoma cells. Furthermore, HDL NPs disrupted colony formation in medulloblastoma and depleted CSC populations in medulloblastoma and Ewing sarcoma. Altogether, our findings provide proof of principle for the development of a novel targeted approach for the treatment of medulloblastoma using HDL NPs. These findings present HDL-mimetic nanoparticles as a promising therapy for sonic hedgehog (SHH) subtype medulloblastoma and possibly other hedgehog-driven cancers.<\/jats:p>","DOI":"10.1038\/s41598-017-18100-8","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T11:21:30Z","timestamp":1516015290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma"],"prefix":"10.1038","volume":"8","author":[{"given":"Jonathan B.","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Rink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-850X","authenticated-orcid":false,"given":"Frank","family":"Eckerdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Clymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Shad","family":"Thaxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas C.","family":"Platanias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"key":"18100_CR1","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/pbc.26042","volume":"63","author":"L Lafay-Cousin","year":"2016","unstructured":"Lafay-Cousin, L. et al. Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. Pediatr. Blood Cancer 63, 1527\u20131534 (2016).","journal-title":"Pediatr. Blood Cancer"},{"key":"18100_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11864-014-0306-4","volume":"15","author":"AM Martin","year":"2014","unstructured":"Martin, A. M., Raabe, E., Eberhart, C. & Cohen, K. J. Management of pediatric and adult patients with medulloblastoma. Curr. Treat Options Oncol. 15, 581\u2013594 (2014).","journal-title":"Curr. Treat Options Oncol."},{"key":"18100_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11060-017-2409-9","volume":"133","author":"TB Fay-McClymont","year":"2017","unstructured":"Fay-McClymont, T. B. et al. Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. J. Neurooncol. 133, 119\u2013128 (2017).","journal-title":"J. Neurooncol."},{"key":"18100_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis, D. N. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131, 803\u2013820 (2016).","journal-title":"Acta Neuropathol."},{"key":"18100_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s13311-017-0526-y","volume":"14","author":"TC Archer","year":"2017","unstructured":"Archer, T. C., Mahoney, E. L. & Pomeroy, S. L. Medulloblastoma: Molecular Classification-Based Personal Therapeutics. Neurotherapeutics 14, 265\u2013273 (2017).","journal-title":"Neurotherapeutics"},{"key":"18100_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nrneurol.2012.78","volume":"8","author":"PA Northcott","year":"2012","unstructured":"Northcott, P. A., Korshunov, A., Pfister, S. M. & Taylor, M. D. The clinical implications of medulloblastoma subgroups. Nat. Rev. Neurol. 8, 340\u2013351 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"18100_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","volume":"123","author":"MD Taylor","year":"2012","unstructured":"Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123, 465\u2013472 (2012).","journal-title":"Acta Neuropathol."},{"key":"18100_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.chembiol.2017.02.010","volume":"24","author":"F Wu","year":"2017","unstructured":"Wu, F., Zhang, Y., Sun, B., McMahon, A. P. & Wang, Y. Hedgehog Signaling: From Basic Biology to Cancer Therapy. Cell Chem. Biol. 24, 252\u2013280 (2017).","journal-title":"Cell Chem. Biol."},{"key":"18100_CR9","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3389","volume":"19","author":"D Amakye","year":"2013","unstructured":"Amakye, D., Jagani, Z. & Dorsch, M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat. Med. 19, 1410\u20131422 (2013).","journal-title":"Nat. Med."},{"key":"18100_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/pmic.201500353","volume":"16","author":"A Hentschel","year":"2016","unstructured":"Hentschel, A., Zahedi, R. P. & Ahrends, R. Protein lipid modifications\u2013More than just a greasy ballast. Proteomics 16, 759\u2013782 (2016).","journal-title":"Proteomics"},{"key":"18100_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.molcel.2017.02.015","volume":"66","author":"X Xiao","year":"2017","unstructured":"Xiao, X. et al. Cholesterol Modification of Smoothened Is Required for Hedgehog Signaling. Mol. Cell 66, 154\u2013162e110 (2017).","journal-title":"Mol. Cell"},{"key":"18100_CR12","doi-asserted-by":"crossref","unstructured":"Huang, P. et al. Cellular Cholesterol Directly Activates Smoothened in Hedgehog Signaling. Cell 166, 1176\u20131187 e1114, (2016).","DOI":"10.1016\/j.cell.2016.08.003"},{"key":"18100_CR13","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1073\/pnas.1213657110","volume":"110","author":"S Yang","year":"2013","unstructured":"Yang, S. et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc. Natl. Acad. Sci. USA 110, 2511\u20132516 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"18100_CR14","doi-asserted-by":"publisher","first-page":"11219","DOI":"10.18632\/oncotarget.14494","volume":"8","author":"KM McMahon","year":"2017","unstructured":"McMahon, K. M. et al. Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. Oncotarget 8, 11219\u201311227 (2017).","journal-title":"Oncotarget"},{"key":"18100_CR15","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1021\/acs.molpharmaceut.7b00710","volume":"14","author":"JS Rink","year":"2017","unstructured":"Rink, J. S. et al. Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin. Mol. Pharm. 14, 4042\u20134051 (2017).","journal-title":"Mol. Pharm."},{"key":"18100_CR16","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.1021\/pr100403q","volume":"9","author":"KC Queiroz","year":"2010","unstructured":"Queiroz, K. C. et al. Human plasma very low density lipoprotein carries Indian hedgehog. J. Proteome Res. 9, 6052\u20136059 (2010).","journal-title":"J. Proteome Res."},{"key":"18100_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.prp.2016.03.011","volume":"212","author":"J Li","year":"2016","unstructured":"Li, J. et al. Up-regulated expression of scavenger receptor class B type 1 (SR-B1) is associated with malignant behaviors and poor prognosis of breast cancer. Pathol. Res. Pract. 212, 555\u2013559 (2016).","journal-title":"Pathol. Res. Pract."},{"key":"18100_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3389\/fphar.2016.00466","volume":"7","author":"LK Mooberry","year":"2016","unstructured":"Mooberry, L. K., Sabnis, N. A., Panchoo, M., Nagarajan, B. & Lacko, A. G. Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging. Front. Pharmacol. 7, 466 (2016).","journal-title":"Front. Pharmacol."},{"key":"18100_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"18100_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/neuonc\/4.2.75","volume":"4","author":"N Aldosari","year":"2002","unstructured":"Aldosari, N. et al. Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. Neuro. Oncol. 4, 75\u201385 (2002).","journal-title":"Neuro. Oncol."},{"key":"18100_CR21","doi-asserted-by":"publisher","first-page":"8442","DOI":"10.18632\/oncotarget.2319","volume":"5","author":"F Eckerdt","year":"2014","unstructured":"Eckerdt, F. et al. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. Oncotarget 5, 8442\u20138451 (2014).","journal-title":"Oncotarget"},{"key":"18100_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/978-3-319-16555-4_6","volume":"166","author":"KM McMahon","year":"2015","unstructured":"McMahon, K. M. et al. Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. Cancer Treat. Res. 166, 129\u2013150 (2015).","journal-title":"Cancer Treat. Res."},{"key":"18100_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-015-0087-z","volume":"13","author":"D Schorghofer","year":"2015","unstructured":"Schorghofer, D. et al. The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence. Reprod. Biol. Endocrinol. 13, 88 (2015).","journal-title":"Reprod. Biol. Endocrinol."},{"key":"18100_CR24","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1158\/0008-5472.CAN-03-0675","volume":"64","author":"WM Cao","year":"2004","unstructured":"Cao, W. M. et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 64, 1515\u20131521 (2004).","journal-title":"Cancer Res."},{"key":"18100_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s003810100496","volume":"17","author":"CH Rickert","year":"2001","unstructured":"Rickert, C. H. & Paulus, W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv. Syst. 17, 503\u2013511 (2001).","journal-title":"Childs Nerv. Syst."},{"key":"18100_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ccell.2016.03.002","volume":"29","author":"TN Phoenix","year":"2016","unstructured":"Phoenix, T. N. et al. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell 29, 508\u2013522 (2016).","journal-title":"Cancer Cell"},{"key":"18100_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/17425247.2014.866089","volume":"11","author":"KM McMahon","year":"2014","unstructured":"McMahon, K. M. & Thaxton, C. S. High-density lipoproteins for the systemic delivery of short interfering RNA. Expert Opin. Drug Deliv. 11, 231\u2013247 (2014).","journal-title":"Expert Opin. Drug Deliv."},{"key":"18100_CR28","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1002\/adfm.201602600","volume":"26","author":"KM McMahon","year":"2016","unstructured":"McMahon, K. M., Plebanek, M. P. & Thaxton, C. S. Properties of Native High-Density Lipoproteins Inspire Synthesis of Actively Targeted In Vivo siRNA Delivery Vehicles. Adv. Funct. Mater. 26, 7824\u20137835 (2016).","journal-title":"Adv. Funct. Mater."},{"key":"18100_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/neuonc\/now247","volume":"19","author":"RL Bowman","year":"2017","unstructured":"Bowman, R. L., Wang, Q., Carro, A., Verhaak, R. G. & Squatrito, M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro. Oncol. 19, 139\u2013141 (2017).","journal-title":"Neuro. Oncol."},{"key":"18100_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature11327","volume":"488","author":"PA Northcott","year":"2012","unstructured":"Northcott, P. A. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488, 49\u201356 (2012).","journal-title":"Nature"},{"key":"18100_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/415436a","volume":"415","author":"SL Pomeroy","year":"2002","unstructured":"Pomeroy, S. L. et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436\u2013442 (2002).","journal-title":"Nature"},{"key":"18100_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1021\/nn2035457","volume":"6","author":"AJ Luthi","year":"2012","unstructured":"Luthi, A. J. et al. Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano. 6, 276\u2013285 (2012).","journal-title":"ACS Nano."},{"key":"18100_CR33","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1021\/nl1041947","volume":"11","author":"KM McMahon","year":"2011","unstructured":"McMahon, K. M. et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett. 11, 1208\u20131214 (2011).","journal-title":"Nano Lett."},{"key":"18100_CR34","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1021\/ja808856z","volume":"131","author":"CS Thaxton","year":"2009","unstructured":"Thaxton, C. S., Daniel, W. L., Giljohann, D. A., Thomas, A. D. & Mirkin, C. A. Templated spherical high density lipoprotein nanoparticles. J. Am. Chem. Soc. 131, 1384\u20131385 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"18100_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1161\/ATVBAHA.109.199158","volume":"30","author":"M de la Llera-Moya","year":"2010","unstructured":"de la Llera-Moya, M. et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 30, 796\u2013801 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"18100_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2144\/000114372","volume":"60","author":"F Eckerdt","year":"2016","unstructured":"Eckerdt, F. et al. A simple, low-cost staining method for rapid-throughput analysis of tumor spheroids. Biotechniques 60, 43\u201346 (2016).","journal-title":"Biotechniques"},{"key":"18100_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu, Y. & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70\u201378 (2009).","journal-title":"J. Immunol. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18100-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18100-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18100-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:14:58Z","timestamp":1671585298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18100-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["18100"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-18100-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,19]]},"assertion":[{"value":"29 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.S.T. founded a biotech company (AuraSense, LLC) that licensed the HDL nanoparticle technology from Northwestern University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1211"}}